Zhang J, Lv PY, Zhao X, Liu ML, et al. Real-world effectiveness and safety of recombinant human endostatin plus PD-1 inhibitors and chemotherapy as first-line treatment for EGFR/ALK-negative, advanced or metastatic non-small cell lung cancer. BMC Cancer 2024;24:967.
PMID: 39112947